Search
NUC B1000
go.drugbank.com/drugs/DB05242Experimental[F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid
AdPEDF
go.drugbank.com/drugs/DB05138ExperimentalIt has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors
Gepefrine
go.drugbank.com/drugs/DB13703ExperimentalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeRo 24-7429
go.drugbank.com/drugs/DB16062InvestigationalRo 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).
PRO-542
go.drugbank.com/drugs/DB05793InvestigationalPRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells.
INCB13739
go.drugbank.com/drugs/DB05064InvestigationalIt is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes
Chloropyramine
go.drugbank.com/drugs/DB08800InvestigationalIt is also indicated for Quincke's edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock. … Chlorpyramine is a first generation antihistamine used in Eastern European countries to treat bronchial asthma as well as allergice rhinitis, allergic conjunctivitis, and other allergic reactions.
Glatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248870] Originally, glatiramer acetate was designed as a stimulant of myelin basic protein (MBP), a myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune … [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017.
Filanesib
go.drugbank.com/drugs/DB06040InvestigationalFilanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.